- $67.94m
- $118.00m
- $81.67m
Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Akoya Biosciences Q1 Gross Margin 59.3%
Akoya Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Leerink Partners downgrades Quanterix to 'market perform' on Akoya deal risks
Brief: Quanterix And Akoya Biosciences Announce Amended Merger Agreement
Brief: Akoya Biosciences And Singapore Translational Cancer Consortium (STCC) Partner On Super Study Designed To Advance Cancer Immunophenotyping For Patients In Singapore
Brief: Kent Lake Files Definitive Proxy Statement And Sends Letter To Quanterix Shareholders
Brief: Akoya Biosciences - On April 2, Entered Securities Purchase Agreement With Quanterix Corporation
Brief: Tikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya Biosciences
U.S. RESEARCH ROUNDUP-Accolade, Crowdstrike, Marriott International
Akoya Biosciences Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Akoya Biosciences Discloses Termination Fees for Deal With Quanterix
Akoya Biosciences gains on merger deal with Quanterix
Brief: Quanterix To Acquire Akoya Biosciences
Brief: Quanterix Is Close To All-Stock Deal For Akoya Bioscience - Bloomberg News
U.S. STOCKS ON THE MOVE-FuelCell Energy, consumer goods stocks, Rocket Companies
U.S. STOCKS ON THE MOVE-OneStream, FuelCell Energy, Alibaba
U.S. STOCKS ON THE MOVE-Alibaba, Palantir, Eyenovia
Akoya Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary